Global Dementia Associated with Alzimer's Disease Market Size By Type (Cholinergic/ Cholinesterase (ChE) Inhibitors, Memantine), By Application (Hospital Pharmacies, Retail), By Region, And Segment Fo...

The Global Dementia Associated with Alzheimer’s Disease Market was valued at USD 7.4 billion in 2023 and is projected to surpass USD 13.5 billion by 2031, growing at a CAGR of 7.9% during the forecast period of 2023–2031. The market’s growth is primarily driven by the rising prevalence of Alzheimer’s disease worldwide, increasing elderly population, advancements in neurodegenerative disease research, and the expansion of early diagnostic tools and treatment options. With Alzheimer’s disease accounting for over 60% of dementia cases globally, the growing awareness and government initiatives to combat cognitive disorders are fostering market expansion.

Drivers:

Rising Global Prevalence of Alzheimer’s Disease

The increasing incidence of Alzheimer’s disease, especially among the aging population, is a primary driver. As life expectancy improves globally, more individuals are entering the high-risk age bracket for dementia, significantly boosting demand for diagnostics and therapeutics.

Advancements in Biomarker Research and Early Diagnosis

Progress in biomarker-based diagnostics, such as PET imaging and cerebrospinal fluid (CSF) analysis, enables earlier detection and intervention, which can delay disease progression. This innovation is fueling market growth by encouraging proactive care strategies.

Government and NGO Support

Initiatives by governments and health organizations, including funding, awareness campaigns, and national dementia plans, are catalyzing investments in research and healthcare infrastructure focused on Alzheimer’s-related dementia.

Restraints:

Lack of Effective Disease-Modifying Treatments

While symptomatic treatments are available, disease-modifying therapies remain limited. The failure rate in clinical trials for Alzheimer’s drugs is high, making it a risky area for investment and posing a challenge to long-term market sustainability.

High Treatment Costs and Limited Accessibility

Advanced diagnostic tests and treatment options are expensive and may not be covered by insurance, particularly in developing economies. These cost barriers can limit patient access and reduce market penetration.

Opportunity:

Pipeline of Innovative Therapies and Biologics

A rich pipeline of monoclonal antibodies, gene therapies, and novel small molecules targeting amyloid-beta and tau proteins presents a significant opportunity. Success in clinical trials could transform the treatment landscape over the next decade.

Growing Demand in Emerging Markets

Emerging economies, especially in Asia-Pacific and Latin America, are witnessing a surge in geriatric populations and healthcare investments, creating a favorable environment for the expansion of Alzheimer’s-related dementia treatment solutions.

Market by System Type Insights:

Therapeutics accounted for the largest market share in 2023, driven by widespread use of cholinesterase inhibitors and NMDA receptor antagonists. However, diagnostics are anticipated to witness the fastest growth during the forecast period, spurred by increasing adoption of biomarker-based and imaging-based early diagnostic tools.

Market by End-use Insights:

Hospitals held the dominant position in 2023, supported by their advanced infrastructure and multidisciplinary care models. The homecare settings segment is expected to grow significantly due to the rising preference for non-institutionalized care and increasing use of digital health platforms for monitoring and support.

Market by Regional Insights:

North America led the global market in 2023, driven by high awareness, strong research funding, and advanced healthcare systems. Asia-Pacific is projected to exhibit the fastest CAGR through 2031, propelled by demographic shifts, increasing healthcare investments, and rising recognition of neurodegenerative disorders in countries like China, Japan, and India.

Competitive Scenario:

Key players in the Global Dementia Associated with Alzheimer’s Disease Market include Biogen Inc., Eisai Co. Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Novartis AG, Pfizer Inc., Johnson & Johnson, Acadia Pharmaceuticals, and Lundbeck A/S. These companies are focused on expanding clinical pipelines, obtaining regulatory approvals, and forming strategic alliances to drive innovation and market expansion.

Scope of Work – Global Dementia Associated with Alzheimer’s Disease Market

Report Metric Details

Market Size (2023) USD 7.4 billion

Projected Market Size (2031) USD 13.5 billion

CAGR (2023–2031) 7.9%

Market Segments By System Type (Therapeutics, Diagnostics), By End-use (Hospitals, Homecare), By Region

Growth Drivers Rising prevalence of Alzheimer’s disease, early diagnostics, government initiatives

Opportunities Biologic therapies pipeline, emerging market expansion

Key Market Developments:

2023: Biogen and Eisai’s Alzheimer’s drug Leqembi (lecanemab) received full FDA approval, marking a significant milestone in disease-modifying treatments.

2024: Eli Lilly advanced donanemab, a promising anti-amyloid therapy, to Phase III clinical trials, showing encouraging early results.

2025: Roche announced the launch of a next-generation digital cognitive assessment tool for early-stage Alzheimer’s screening in partnership with leading academic institutions.

FAQs:

1) What is the current market size of the Global Dementia Associated with Alzheimer’s Disease Market?

The market was valued at USD 7.4 billion in 2023.

2) What is the major growth driver of the Global Dementia Associated with Alzheimer’s Disease Market?

The primary growth driver is the rising global prevalence of Alzheimer’s disease and growing demand for early diagnosis and treatment.

3) Which is the largest region during the forecast period in the Global Dementia Associated with Alzheimer’s Disease Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to grow the fastest through 2031.

4) Which segment accounted for the largest market share in Global Dementia Associated with Alzheimer’s Disease Market?

The therapeutics segment led the market in 2023, driven by widespread adoption of symptomatic treatment drugs.

5) Who are the key market players in the Global Dementia Associated with Alzheimer’s Disease Market?

Key players include Biogen Inc., Eisai Co. Ltd., Eli Lilly and Company, Roche, Pfizer, and Novartis.